North America Sports Medicine Market 2020 to Witness Excellent Long-Term Growth Outlook

Pune, New York, USA, November 24 2020 (Wiredrelease) Research Dive :According to a new report published by Research Dive, titled, Sports Medicine Devices Market : North America Opportunity Analysis and Industry Forecast, 2018-2025,the North America sports medicine devices market was valued at $3,580 million in 2018, and is expected to reach $5,382 million by 2025, registering a CAGR of 6.7% from 2019 to 2025.

Sports medicine deals with the physical fitness of athletes. It is used for prevention and treatment of injuries related to sports and exercise. Common sport injuries include anterior cruciate ligament (ACL) tears, ankle sprains, muscle cramps, and shin splints. Sports medicine doctors are trained to restore function to injured patients, so they can get moving again as soon as possible. Demand for sports medicine devices has increased considerably, owing to active participation of athletes in various sports across different countries. Various aspects of sports medicine such as indulging in sports activities for fitness, recommendations for physical training, and sports injury prevention treatment further contribute toward the market growth.

Connect with Analyst to Reveal How COVID-19 Impacting On Market: https://www.researchdive.com/connect-to-analyst/3

Rise in incidence of sports-related injuries in the young population majorly drives the growth of the sports medicine devices market. Moreover, sports injuries have become highly prevalent among the young population, owing to increase in participation in sports. In addition, increase in initiatives by governments of various countries to promote sports activities and rise in demand for minimally invasive surgeries boost the market growth. Furthermore, easily accessible and advanced treatment products related to sports medicine for quick easy recovery fuel the demand for sports medicine. However, lack of skilled professionals as well as inappropriate administration and guidelines in the field of sports medicine hamper the growth of the market. Conversely, rising influx of athletes and technological advancements in sports medicine are expected to offer remunerative opportunities for the North America sports medicine market players.

The body reconstruction repair segment is anticipated to dominate the market during the forecast period. This is attributed to the fact that body reconstruction repair products are majorly used in the treatment and prevention of sport-related injuries. Among body reconstruction repair products, the bone/cartilage repair reconstruction segment is expected to register the highest CAGR during the forecast period. Considering body support recovery products, the support devices braces segment was the highest revenue contributor in 2018, accounting for five-ninths share. The knee injuries segment is estimated to grow at the highest CAGR from 2018 to 2025, as athletes frequently suffer from such injuries. Sports medicines are principally employed in the treatment of knee injuries, owing to increase in incidence of meniscus tear among sportspersons.

Download Exclusive Free Sample Copy of the Report at: https://www.researchdive.com/download-sample/3

Key Findings of the Sports Medicine Devices Market:

The body support recovery segment is anticipated to generate the second highest revenue during the forecast period.
Artificial joint implants serve to be the highest contributor to the orthopedic sports medicine devices market in 2018 and is expected to maintain this dominance

Read more

Long-Term Ocrelizumab Benefits Seen in PPMS

Early, continuous treatment with ocrelizumab (Ocrevus) led to sustained slowing of disease progression in primary progressive multiple sclerosis (PPMS), long-term data from the ORATORIO extension study suggested.

Most measures of 6-month confirmed disability progression, including Expanded Disability Status Scale (EDSS) scores, were better in PPMS patients who started treatment early in ORATORIO compared with patients who started with placebo before joining the open-label extension, reported Jerry Wolinsky, MD, of the University of Texas McGovern Medical School in Houston, and co-authors. No new safety signals emerged compared with the double-blind phase of ORATORIO.

“Compared with patients switching from placebo, earlier and continuous ocrelizumab treatment provided sustained benefits on measures of disease progression over the 6.5 study years of follow-up,” the researchers wrote in Lancet Neurology.

“Although this study shows the benefit of earlier intervention with ocrelizumab in primary progressive disease, progression remains an important unmet need in multiple sclerosis,” they noted. “Further research should focus on how the potential benefits described in this study might be improved upon, particularly over longer time periods.”

PPMS is characterized by gradual disability accumulation from disease onset, sometimes with superimposed relapses or MRI lesion activity. Ocrelizumab, an anti-CD20 monoclonal antibody, is the only disease-modifying therapy approved to treat PPMS currently. The FDA’s decision was based on ORATORIO results, which showed that treatment with intravenous 600-mg ocrelizumab every 6 months reduced 3-month confirmed worsening of EDSS scores compared with placebo.

“The efficacy of ocrelizumab versus placebo shown in ORATORIO was recapitulated as participants switched from placebo to ocrelizumab upon entering the open-label extension,” noted Deja Rose, MD, and Jeffrey Cohen, MD, both of the Cleveland Clinic in Ohio, in an accompanying editorial.

But several questions remain, Rose and Cohen pointed out: “Can we extrapolate these results in primary progressive multiple sclerosis to secondary progressive multiple sclerosis (a more common form of progressive multiple sclerosis, which occurs after a relapsing-remitting course)? Are there rare or late adverse events that have not yet been seen?”

“Some studies, but not others, have suggested that the proportion of patients treated with anti-CD20 monoclonal antibodies is higher among patients with severe COVID-19 outcomes than among the overall population with multiple sclerosis,” they added. “Further research is needed to investigate whether anti-CD20 monoclonal antibodies reduce protective immunity after SARS-CoV-2 infection or, when available, vaccination.”

ORATORIO was a double-blind phase III trial of PPMS patients with an EDSS score of 3.0-6.5. Patients who had previous treatment with B cell-targeted therapies or other immunosuppressive medications were excluded.

Participants were randomly assigned to receive either intravenous infusion of 600-mg ocrelizumab (two 300-mg infusions, 14 days apart) or placebo every 24 weeks for at least 120 weeks. After the double-blind phase, patients entered an extended controlled period, followed by an optional open-label extension where they could continue ocrelizumab or switch from placebo to the drug. The last patient entered the open-label extension in April 2016.

Overall, 544 of 732 participants completed the double-blind period, and 527 people entered the open-label extension phase. Time to onset

Read more

JetBlue and Northwell Direct Partner to Provide Long-Term Health Solutions to COVID-19

Northwell Direct and JetBlue, New York’s Hometown Airline, (NASDAQ: JBLU) today announced that they are partnering to provide the airline with a comprehensive set of COVID-19 services and programs to support its crewmembers (employees) across JetBlue’s operation and add a clinical layer to the airline’s Safety From the Ground Up program.

The customized set of solutions from Northwell Direct – a Northwell Health company that provides a broad range of health care solutions to employers in the tri-state area – will support JetBlue as it considers testing approaches for its teams in New York City, clinical concierge services for crewmembers, and consulting and advisory services for JetBlue’s leadership. The program, which is expected to evolve and expand based on needs, is designed to detect and prevent COVID-19 and to aid in the recovery of the airline industry.

The suite of services and the ongoing evolution of the program will collaboratively be designed by clinical experts at Northwell Health, which has treated over 93,000 patients with COVID-19, and JetBlue’s leadership, and are based on science and the latest medical knowledge around COVID-19 and the specific needs of the company’s crewmembers. Tests conducted as part of any JetBlue programs will be processed by Northwell Health Labs, which has invested more than $30 million in COVID-19 testing equipment and supplies since the start of the pandemic – more than any other hospital-based lab in the country.

In addition, the program allows JetBlue to offer tri-state crewmembers 24/7 access to expert guidance and assistance with questions or concerns about the virus. These clinical concierge services provided by Northwell Health Solutions, Northwell’s care management arm, if appropriate, will also be able to provide fast and seamless navigation to care. These crewmembers will also have access to Northwell Health’s COVID Ambulatory Resource Support (CARES) program, which offers hospital-level care in the safety and comfort of home.

“JetBlue’s leaders reached out to Northwell Direct because they believe, as we do, that the path to recovery is built on a foundation of health and safety,” said Nick Stefanizzi, CEO of Northwell Direct. “We’re proud to partner with them in supporting their crewmembers and in working to restore this vital sector of the economy.”

The arrangement also provides JetBlue leadership with consulting and advisory services from Northwell Health clinical leaders to ensure corporate strategies are evidence-based and to take advantage of the latest advances in the fight against the new coronavirus. The multi-layered set of protective strategies complement JetBlue’s extensive Safety from the Ground Up program, which, along with maintaining healthy crewmembers, focuses on travel flexibility, clean air and surfaces, and more space with fewer touchpoints.

“Keeping our crewmembers healthy is an important pillar of our Safety from the Ground Up program. By partnering with a healthcare leader like Northwell, we are leveraging their experience to provide our crewmembers with confidence that they are healthy,” said Joanna Geraghty, president and chief operating officer, JetBlue. “Our crewmembers are doing an exceptional job in these challenging times, and are

Read more

Health systems are seeking long-term health tech tie-ups

  • Hospital CIOs are currently eyeing health tech partners for the long haul.
  • And health systems that demonstrate clear ROI, like Amwell and Health Catalyst, are in a solid position to win deals.
  • Insider Intelligence publishes hundreds of insights, charts, and forecasts on the Digital Health industry with the Digital Health Briefing. For a limited time, you can try the Briefing for a full week for just $1!

Health system leaders think health tech companies have long-term potential, and they’re starting to see value in these companies beyond a COVID-19-colored lens: A survey of 20 health system CIOs and innovation leaders shows over 60% are interested in investing in platforms that target patient experience, telehealth, and operational efficiency.

US health systems most coveted digital health solutions

Health systems are eyeing health tech partners.

Business Insider Intelligence


The coronavirus pandemic severely impacted health systems’ budgets, which fast-tracked health system-health tech partnerships: 

  • Health systems faced steep financial losses, leaving them scrambling for ways to restore revenue. From March 1 to June 30 of this year, US hospitals and health systems lost nearly $203 billion, per the AHA. These losses can be largely attributed to lower patient volumes, cancellations of elective procedures, and the costs of additional logistics, support, and PPE supplies. Despite a $175 billion relief package from Congress, health systems still had to invest in care solutions and resort to furloughing or laying off employees for some financial padding.  
  • To contend with newfound healthcare delivery and operational woes, health systems quickly turned to digital solutions to stay afloat. Virtual care became a go-to healthcare delivery option almost overnight—telehealth vendors secured millions in funding from health systems’ VC arms as they looked to implement digital health solutions to recoup revenue. For instance, Genesis Health System invested in Bright.md to virtualize and streamline its healthcare delivery operations—which allowed it to reach patients amid widespread stay-at-home orders and optimize its provider workforce. 

Health tech startups that prove they have ROI potential will usher in a wave of tie-ups with eager health systems. With health systems already struggling to hold onto their shrinking budgets, startups will have to prove clear value to reel in health system customers: 50% of health systems think their budgets will not normalize for at least one year, per Dreamit Ventures-MedCityNews.

A 2020 Center for Connected Medicine survey of 130 health system executives shows telehealth tools and virtualization of administrative tasks produced the highest ROIs—which will likely capture the interest of health systems.

For example, Northwell Health, one of the largest health systems in the US, reported a $1.2 billion financial loss due to the pandemic—yet in August, the health system partnered with health data company, Health Catalyst, to leverage its analytics capabilities to boost precision medicine efforts and reduce spending on extraneous tests and procedures. 

Want to read more stories like this one? Here’s how you can gain access:

  1. Join other Insider Intelligence clients who receive this Briefing, along with other Digital Health forecasts, briefings, charts, and research reports to their inboxes each day. >> Become a Client
  2. Explore
Read more

Outbreak At NH Long-Term Care Facility Ends; Another Death: Data

CONCORD, NH — State health officials announced Thursday that a coronavirus outbreak at a long-term case facility in Windham had officially ended.

The Warde Health Center Windham was moved out of outbreak status after the discovery of three residents and two staffers who had contracted COVID-19. There are three institutional associated outbreaks that are still active in New Hampshire: The Bedford Hills Center, where 15 have died as well as 61 residents and 24 staffers were infected, the Pine Rock Manor in Warner where two people have died, 44 residents, and nine staffers have contracted the virus, and St. Teresa Rehabilitation and Nursing Center Manchester, where 19 residents and five staffers caught the virus.

Officials also reported the 470th fatality due to or because of complications from COVID-19 in the Granite State — a man from who was 80 years of age or older and lived in a long-term care setting in Hillsborough County.

“We offer our sympathies to the family and friends,” the State Joint Information Center said. “In New Hampshire since the start of the pandemic, there have been a total of 9,994 cases of COVID-19 diagnosed with 765 (8 percent) of those having been hospitalized.”

Another 82 new positive test results were found by the state after collecting nearly 9,000 polymerase chain reaction specimens Wednesday with Thursday’s numbers upgraded slightly. A little more than 400 tests are pending for a daily positivity rate of 0.8 percent.

Of the new cases, 12 were children and 56 percent were female. The state is still investigating three of the new cases with 12 cases in total still being eyed by state officials. The new cases reside in Rockingham County, 28, with 14 who live in Hillsborough County outside of Manchester and Nashua, seven in Merrimack County, and eight in Nashua. Manchester currently has the most active cases in the state — 98, followed by Nashua (64), Bedford (55), Concord (43), and Warner (42). Portsmouth has 24, Salem has 21, Londonderry has 19, and Merrimack has 18 active cases. Windham has nine cases, Exeter and Hampton have eight, Milford has seven, North Hampton has five, and Amherst has between one and four cases.

In New Hampshire, 323,173 people have been tested via 561,032 PCR tests. Approximately 4,200 people are under public health monitoring.

Several K-12 schools have reported new COVID-19 cases. St. Paul’s School in Concord reported a second active new case; the Matthew Thornton Elementary School in Londonderry reported its second active case; and the Boscawen Elementary School and the Conway Elementary School reported their first cases Thursday. There are 65 positive test results connected to schools and school activities.

ALSO READ:

Stop The Spread Of COVID-19

The COVID-19 virus is spread through respiratory droplets, usually through coughing and sneezing, and exposure to others who are sick or might be showing symptoms.

Health officials emphasize residents should follow these recommendations:

  • Avoid any domestic and international travel, especially on public transportation such as buses, trains, and airplanes.

  • Practice social

Read more

Long-term problems in younger low-risk COVID-19 patients; flu shot may offer some protection

By Nancy Lapid



a man standing in a room: The coronavirus disease (COVID-19) outbreak continues in France


© Reuters/Pascal Rossignol
The coronavirus disease (COVID-19) outbreak continues in France

(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Long-term health problems seen in low-risk COVID-19 patients

Young, healthy adults with COVID-19 who do not require hospitalization are still at risk for long-term health problems, Oxford University researchers found. They studied 201 recovering UK patients with an average age of 44, more than 90% of whom did not have risk factors such as diabetes, high blood pressure, or heart disease. Only 18% had been sick enough to be hospitalized. At an average of 140 days after their symptoms began, 98% were still fatigued, 92% had heart and lung symptoms, 88% had muscle aches, 87% had breathlessness, 83% headaches, and 73% gastrointestinal symptoms. Organ damage was more common among those who had been hospitalized. But it was not limited to that group as 66% of the patients had impairment of at least one organ. Magnetic resonance imaging (MRI) scans showed mild damage to lungs in 33%, heart in 32%, pancreas in 17%, kidneys in 12%, liver in 10% and spleen in 6%. The researchers say their study, posted on Friday on medRxiv ahead of peer review, cannot prove the virus caused these later issues. But it does suggest long-term monitoring of organ function will be necessary even in relatively low-risk patients. (https://bit.ly/2IAR83N)

Flu shot may help protect against COVID-19

Flu vaccines may help the body defend itself against COVID-19, according to a Dutch study that found hospital workers who got a flu shot last winter were less likely to become infected with the new coronavirus. In test tube experiments, the researchers saw that last winter’s flu vaccine could prime healthy cells to respond more effectively not just to the flu, but also to the new coronavirus. When they analyzed COVID-19 rates among staff at their hospital, they found the number of infections was 39% lower among those who had gotten a flu vaccine. “These data, combined with similar recent independent reports, argue for a possible beneficial effect of influenza vaccination against both influenza and COVID-19,” the researchers say. “This could mean that the flu vaccine could offer partial protection against both infections this winter.” They posted their report on medRxiv on Friday ahead of peer review. “We thought it was important to publish these results already because the flu shot is made available to a large group of people,” study leader Mihai Netea of Radboud University Medical Center said in a news release. (https://bit.ly/35bqEgV)

Pandemic increases need for strength training by elderly

Older people “urgently” need to be doing resistance exercises, also known as strength training, during the pandemic, to counteract the effects of physical inactivity and to make sure they retain at least the same level of muscle function they had prior to lockdowns and stay-at-home orders, doctors advise. Social distancing measures

Read more